← Human Trials & Peer-Reviewed Studies
Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-A pilot study
Plain-language guide to PMID 19261371 (2009): pilot clinical trial study of Goserelin in 20 patients, endometriosis.
Key Facts
- PMID
- 19261371
- Journal
- European journal of obstetrics, gynecology, and reproductive biology
- Year
- 2009
- Study type
- Clinical Trial
- Authors
- Lossl K et al. (8 authors)
- DOI
- 10.1016/j.ejogrb.2009.02.001
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Goserelin in the context of endometriosis, published as a clinical trial.
Combined administration of aromatase inhibitor and GnRH-agonist may efficiently suppress estrogen biosynthesis through a combined pituitary, ovarian, peripheral and "in situ" action.
The aim of this study was to test the concept of combined down-regulation prior to IVF in patients with endometriomas.
Who Took Part
The abstract describes 20 patients taking part.
PubMed indexes the participants as adults, women only.
Prospective pilot study in a university-based tertiary fertility clinic including 20 infertile patients with endometriomas undergoing IVF/ICSI.
How the Study Was Run
The researchers set it up as a pilot study.
It is described as a pilot, a small early test of whether a larger Goserelin study would be practical.
Controlled ovarian stimulation was initiated from Day 70.
Outcome measures were change in endometriomal volume and serum CA125 during down-regulation, standard IVF parameters including pregnancy and delivery rate, and endocrine response.
The paired T test and Wilcoxon Signed Rank test were used to analyse paired differences.
What Was Measured
Topics PubMed links to this paper include Anastrozole, Aromatase Inhibitors, CA-125 Antigen, Down-Regulation, Endometriosis, Estrogens and Fertilization in Vitro.
What This Means in Plain Language
The paper is a pilot study of Goserelin in 20 patients in people with endometriosis.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2009 (European journal of obstetrics, gynecology, and reproductive biology), a journal based in Ireland.
More context: the Goserelin compound page, Endometriosis research.
Our Notes on the Compound
Goserelin: A GnRH analog implant (Zoladex) used to lower sex-hormone levels in prostate and breast cancer and gynecologic conditions.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.